Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 343 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Observation for safety Clear all

Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
Interventions: atorvastatin, Tacrolimus, methotrexate; Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Prostatic Neoplasms
Interventions: Registry; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer
Interventions: 99mTc-MIP-1404 Injection, Whole-Body Planar and pelvic SPECT/CT scan; Drug · Diagnostic Test
Lead sponsor: Molecular Insight Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 33
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 26 more

Conditions: Prostatic Neoplasms
Interventions: Radiotherapy, LHRHa, Apalutamide; Radiation · Drug
Lead sponsor: Janssen Pharmaceutica N.V., Belgium; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 691 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 13
States / cities: Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 10 more

Conditions: Fanconi Anemia, Head and Neck Cancer, Squamous Cell Carcinoma, Squamous Cell Cancer of Head and Neck (SCCHN)
Interventions: Metformin, Naproxen Sodium; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Minneapolis, Minnesota • New York, New York

Conditions: Von Willebrand Disease (VWD)
Interventions: VGA039; Drug
Lead sponsor: Vega Therapeutics, Inc; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 14
States / cities: Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 10 more

Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III
Interventions: Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download, Medication intervention, Not Randomized to Device or Medication Intervention; Device · Other
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 826 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 53
States / cities: Mesa, Arizona • Jonesboro, Arkansas • Mission Viejo, California + 47 more

Conditions: Urolithiasis, Stones, Kidney, Renal Stones, Kidney Stones
Interventions: CVAC® SYSTEM, FLEXIBLE AND NAVIGATIONAL URETERAL ACCESS SHEATH (FANS) IN FLEXIBLE URETEROSCOPY (FURS), DIRECT IN-SCOPE SUCTION (DISS) IN FLEXIBLE URETEROSCOPY (FURS), URETEROSCOPY (URS) WITHOUT SUCTION, PERCUTANEOUS NEPHROLITHOTOMY (PCNL); Device · Procedure
Lead sponsor: Calyxo, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Miami, Florida • Wichita, Kansas • Cheektowaga, New York + 6 more

Conditions: Adhesive Capsulitis, Frozen Shoulder
Interventions: Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 30
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 25 more

Conditions: Cystic Fibrosis
Interventions: Ivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 2 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 12
States / cities: Birmingham, Alabama • Denver, Colorado • Atlanta, Georgia + 9 more

Conditions: Infections, Papillomavirus
Interventions: Data collection; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 9 Years to 25 Years · Female only
Enrollment: 1,516 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Friedreich Ataxia
Interventions: Omaveloxolone; Drug
Lead sponsor: Biogen; Industry
Eligibility: 16 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 1 more

Conditions: Post-Meniscectomy Pain Syndrome, Osteoarthritis, Knee
Interventions: NUsurface® Meniscus Implant; Device
Lead sponsor: Phoenix Kinetics; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 13
States / cities: Phoenix, Arizona • La Mesa, California • Long Beach, California + 10 more

Conditions: Cancer, Chemotherapy, Squamous Cell Carcinoma (SCC)
Interventions: Panitumumab-IRDye800; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Wound Heal, Peripheral Artery Disease, Ulcer, Leg, Ulcer Foot, Diabetic Foot Ulcer, Arterial Insufficiency
Interventions: Noxsano Bandage (Healthy Volunteers), Noxsano Bandage (Wound Care); Device
Lead sponsor: OhioHealth; Other
Eligibility: 18 Years to 79 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Inpatient Experience Survey Administration, Inpatient Experience Survey Response, Inpatient Pediatric Care, Inpatient Pediatric Engagement and Shared Decision-Making
Interventions: Text-Only Enrollment Strategy, Text Plus In-Person Enrollment Strategy, Anonymous Safety Reporting with Impact Website, Identified Safety Reporting, Safety Reporting Integration Toolkit; Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years and older
Enrollment: 21,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Los Angeles, California • Oakland, California • Sacramento, California + 5 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Not listed
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 189,426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Retinal Diseases, Stargardt's Disease, Retinitis Pigmentosa
Interventions: Not listed
Lead sponsor: Retina Institute of Hawaii; Other
Eligibility: 50 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 4
States / cities: Hilo, Hawaii • Honolulu, Hawaii • Kahului, Hawaii + 1 more

Conditions: Von Willebrand Disease, Type 3
Interventions: Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates, von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates, Bypassing Agents; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 1 Month and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Sacramento, California • Gainesville, Florida • Lexington, Kentucky + 3 more

Conditions: Critical Illness, Wounds and Injury, Disease Attributes, Pathologic Processes
Interventions: Automated Titration (O2matic); Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Aurora, Colorado • Winston-Salem, North Carolina • Portland, Oregon + 1 more

Conditions: Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk
Interventions: Balfaxar, Kcentra; Drug
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 3,574 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Solid Tumor
Interventions: SGN1; Drug
Lead sponsor: Guangzhou Sinogen Pharmaceutical Co., Ltd; Other
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Gilbert, Arizona • Orange, California • Detroit, Michigan + 1 more

Conditions: Acute Myeloid Leukemia
Interventions: Galinpepimut-S, Azacitidine, Venetoclax, Decitabine, Cytarabine, Observation, GM-CSF, Montanide; Biological · Drug · Other
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • Whittier, California + 14 more

Conditions: Breast Implant
Interventions: NBIR - US National Breast Implant Registry, 410 Arm, BIFs - Breast Implant Follow-Up Study; Other · Device
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 56,460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2029
U.S. locations: 1
States / cities: El Paso, Texas

Search by objective public record fields.

Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation

An Electronic Registry to Improve Adherence to Active Surveillance Monitoring at a Safety-net Hospital

Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia

Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure

Stone Clearance With Aspiration vs Other Technologies: a Real-world Evidence Study

Long-term Follow-up Durability (Efficacy) Study of EN3835 for the Treatment of AC of the Shoulder (Frozen Shoulder)

Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation

Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination

A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors

The SUN Clinical Trial (Safety Utilizing NUsurface Meniscus Implant)

A Project Assessing the Safety and Feasibility of Using Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Ovarian Cancer During Surgical Procedures

Safety and Efficacy of the Noxsano Wound Care Bandage

FIQS Dissemination and Implementation

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Microcurrent Stimulation to Treat Macular Degeneration

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

Strategy to Avoid Excessive Oxygen Using an Autonomous Oxygen Titration Intervention

Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure

Study of SGN1 in Patients With Advanced Solid Tumor

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms